Scientific publications

November 2024
Sarcomas express extra domain B of fibronectin and preclinical patient-derived xenograft models of several sarcoma subtypes are sensitive to the stroma targeting antibody drug conjugate PYX-201 – Abstract #: 1854935
CTOS Poster
November 2024
Associations of the immunomodulatory molecule Siglec-15 gene and protein expression to immune gene signatures as a potential biomarker for Siglec-15 targeted therapy in non-small cell lung cancer – Abstract #: 219
SITC Poster
November 2024
Characterization and prevalence of the novel immunomodulatory protein Siglec-15 expression in tumor cells and macrophages across multiple solid tumor indications – Abstract # 521
SITC Poster
November 2024
PYX-106, a highly differentiated anti-Siglec-15 monoclonal antibody, reverses Siglec-15 mediated immune suppression and enhances cytotoxic activity in human lymphocytes – Abstract #: 567
SITC Poster
April 2024
PYX-201, EDB+FN is an attractive target in oncology: Insights from protein expression analysis of solid tumors – Abstract Number: 2908
AACR Poster
April 2024
PYX-201, a stroma-targeting ADC composed of an anti-EDB+FN antibody conjugated to Auristatin0101, demonstrates strong anti-tumor efficacy across multiple human cancer indications in pre-clinical PDX tumor models – Abstract Number: 742
AACR Poster
April 2024
Extracellular proteolytic cleavage of peptide-linked antibody-drug conjugates promotes bystander killing of cancer cells – Abstract Number: 4837
AACR 2014 Pfizer Poster
April 2024
PYX-106, Gene expression correlation of immune checkpoint molecules Siglec-15 and PD-L1 varies widely by cancer indication – Abstract Number: 1373
AACR Poster
April 2024
Safety and Tolerability of a Novel Anti-HER2 Antibody–Drug Conjugate (PF-06804103) in Patients with HER2-Expressing Solid Tumors: A Phase 1 Dose-Escalation Study (Mol Cancer Ther. 2023 Oct 2;22(10):1191-1203.)
Article
April 2024
Anti-Extra Domain B Splice Variant of Fibronectin Antibody–Drug Conjugate Eliminates Tumors with Enhanced Efficacy When Combined with Checkpoint Blockade (Mol Cancer Ther. 2022 Sep 6;21(9):1462-1472.)
Article
321 Harrison Avenue
11th Floor, Suite 1
Boston, MA 02118
(617) 453-3596 | info@pyxisoncology.com
Pyxis Oncology
Linkedin-in